Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2009 1
2010 5
2011 4
2012 9
2013 5
2014 6
2015 9
2016 8
2017 8
2018 11
2019 11
2020 11
2021 15
2022 18
2023 17
2024 17
2025 7
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year

Filters applied: . Clear all
Quoted phrases not found in phrase index: "Shunsuke Kondo[au]", "(Tokyo women's medical university[ad]) OR (National cancer center[ad)] OR (Tokyo University[ad]) OR (Tokushima University[ad])", "23828517"
Page 1
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody.
Tran B, Voskoboynik M, Kim SW, Lemech C, Carcereny E, Rha SY, Ahn MJ, Felip E, Lee KH, Castañón Álvarez E, Yang JC, Ascierto PA, Provencio Pulla M, Kondo S, Kuboki Y, Freeman D, Song X, Blando J, Eck S, Song FJ, Tang Z, Kuziora M, Gainer SD, Mitchell P, Asare J, Ayyoub A, Achour I, Subramaniam DS, Im SA. Tran B, et al. Among authors: kondo s. Clin Cancer Res. 2026 Feb 17. doi: 10.1158/1078-0432.CCR-25-3447. Online ahead of print. Clin Cancer Res. 2026. PMID: 41701940
Noninvasive detection of pancreatic ductal adenocarcinoma in high-risk patients using miRNA from urinary extracellular vesicles.
Kawase T, Kato Y, Nishihara H, Baba S, Kawasaki T, Kurahara H, Oi H, Kondo S, Okada M, Satake T, Igawa YS, Yoshida T, Kita J, Imura J, Kinoshita K, Yokoyama M, Satomura A, Takayama K, Mikami M, Nishiyama Y, Mizunuma M, Ichikawa Y, Yoshida K. Kawase T, et al. Among authors: kondo s. Front Oncol. 2026 Jan 27;15:1682072. doi: 10.3389/fonc.2025.1682072. eCollection 2025. Front Oncol. 2026. PMID: 41675520 Free PMC article.
PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.
Miyakoshi J, Yoshida T, Uehara Y, Takeyasu Y, Shirasawa M, Fukuda A, Kashima J, Kumagai S, Horinouchi H, Ono H, Shiraishi K, Kohno T, Kondo S, Goto Y, Yamamoto N, Yatabe Y, Hosomi Y, Kurata T, Naoki K, Suzuki T, Ohe Y. Miyakoshi J, et al. Among authors: kondo s. J Immunother Cancer. 2025 Dec 5;13(12):e012880. doi: 10.1136/jitc-2025-012880. J Immunother Cancer. 2025. PMID: 41360425 Free PMC article.
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.
Harding JJ, Oh DY, Mercade TM, Goyal L, Varkaris A, Palmieri LJ, Ikeda M, Kondo S, Bai LY, Ueno M, Chen LT, Papadopoulos KP, Shroff RT, Kizilbash SH, Hollebecque A, Adeva J, Cosman R, Yokota T, Park JO, Turk A, Liao CY, Satoh T, Borad MJ, El-Khoueiry A, Azad N, Jaeckle KA, Loong HH, Yong WP, Bender MH, Varughese SC, Sachdeva D, Radtke DB, Gueorguieva I, Szpurka AM, Chen HR, Liu H, Xu X, Rodon J. Harding JJ, et al. Among authors: kondo s. Clin Cancer Res. 2025 Dec 1;31(23):4920-4932. doi: 10.1158/1078-0432.CCR-25-0174. Clin Cancer Res. 2025. PMID: 41026608 Clinical Trial.
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks.
Kondo S, Kitano S, Sato J, Katsuya Y, Kogawa T, Mizugaki H, Miyamoto I, Iwasawa S, Imaizumi T, Tomita H, Murakami C, Miyake T, Yamamoto N. Kondo S, et al. Invest New Drugs. 2025 Jun;43(3):602-608. doi: 10.1007/s10637-024-01498-0. Epub 2025 May 1. Invest New Drugs. 2025. PMID: 40310568 Free PMC article.
Potential of 6-mm-diameter fully covered self-expandable metal stents for unresectable malignant distal biliary obstruction: a propensity score-matched study.
Yamashige D, Hijioka S, Nagashio Y, Maruki Y, Fukuda S, Yagi S, Okamoto K, Hara H, Hagiwara Y, Agarie D, Takasaki T, Ohba A, Kondo S, Morizane C, Ueno H, Sone M, Saito Y, Okusaka T. Yamashige D, et al. Among authors: kondo s. Clin Endosc. 2025 Jan;58(1):121-133. doi: 10.5946/ce.2024.044. Epub 2024 Jul 29. Clin Endosc. 2025. PMID: 39895273 Free PMC article.
A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study.
Baba S, Kawasaki T, Hirano S, Nakamura T, Asano T, Okazaki R, Yoshida K, Kawase T, Kurahara H, Oi H, Yokoyama M, Kita J, Imura J, Kinoshita K, Kondo S, Okada M, Satake T, Igawa YS, Yoshida T, Yamaguchi H, Ando Y, Mizunuma M, Ichikawa Y, Hida K, Nishihara H, Kato Y. Baba S, et al. Among authors: kondo s. EClinicalMedicine. 2024 Nov 12;78:102936. doi: 10.1016/j.eclinm.2024.102936. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39764541 Free PMC article.
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Wilding B, Woelflingseder L, Baum A, Chylinski K, Vainorius G, Gibson N, Waizenegger IC, Gerlach D, Augsten M, Spreitzer F, Shirai Y, Ikegami M, Tilandyová S, Scharn D, Pearson MA, Popow J, Obenauf AC, Yamamoto N, Kondo S, Opdam FL, Bruining A, Kohsaka S, Kraut N, Heymach JV, Solca F, Neumüller RA. Wilding B, et al. Among authors: kondo s. Cancer Discov. 2025 Jan 13;15(1):119-138. doi: 10.1158/2159-8290.CD-24-0306. Cancer Discov. 2025. PMID: 39248702 Free PMC article.
142 results